Novo Nordisk reported positive early trial results for its new obesity drug candidate, amycretin, showing a 13.1% weight loss after 12 weeks. This exceeded the 6% loss seen in trials for the company's blockbuster Wegovy over the same period. The Phase II trial for amycretin will begin in the second half of 2024, with results expected in early 2026. Novo Nordisk shares jumped 5% on the news, hitting a fresh record high. Novo has gained more than 26% in 2024 from strong demand for Wegovy and Ozempic.